On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

Over the past year, the Ger­man-based life sci­ence group Sar­to­rius has made sev­er­al moves to grow the com­pa­ny in the cell and gene ther­a­py space, and its lat­est move sees the com­pa­ny con­tin­u­ing that track as it is com­mit­ting to a nine-fig­ure deal to bring UK-based Al­bumedix un­der its wing.

The deal will have Sar­to­rius ac­quir­ing 100% of the com­pa­ny from pri­vate in­vestors for £415 mil­lion, or around $502 mil­lion. Al­bumedix, based in the city of Not­ting­ham, UK, is a man­u­fac­tur­er of al­bu­min-based prod­ucts. Al­bu­min serves as a ma­jor in­gre­di­ent in cell cul­ture me­dia and is used as an an­i­mal-free ad­di­tive in the man­u­fac­tur­ing of vac­cines, cell ther­a­pies and vi­ral ther­a­pies. The trans­ac­tion is ex­pect­ed to close be­fore the end of Q3 of 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER